In this third up date of the Cochrane review , there were no differences in effects of homocysteine-lowering interventions in the form of supplements of vitamins B6 , B9 or B12 given alone or in combination comparing with placebo on myocardial infa rct ion , death from any cause or adverse events .
BACKGROUND Cardiovascular disease , which includes coronary artery disease , stroke and peripheral vascular disease , is a leading cause of death worldwide .
Homocysteine is an amino acid with biological functions in methionine metabolism .
A postulated risk factor for cardiovascular disease is an elevated circulating total homocysteine level .
The impact of homocysteine-lowering interventions , given to patients in the form of vitamins B6 , B9 or B12 supplements , on cardiovascular events has been investigated .
This is an up date of a review previously published in 2009 , 2013 , and 2015 .
OBJECTIVES To determine whether homocysteine-lowering interventions , provided to patients with and without pre-existing cardiovascular disease are effective in preventing cardiovascular events , as well as reducing all-cause mortality , and to evaluate their safety .
Homocysteine, vitamin B12 and folate levels in Iranian patients with ischemic stroke
Abstract Objectives : Homocysteine , folate , and some group B vitamins have been proposed as a cause of Cerebro-Vascular Accidents ( CVA ) . We conducted a case-control study to compare the plasma levels of folate , vitamin B12 and homocysteine in Iranian subjects with and without cerebro-vascular accident . Methods : We recruited 82 patients with ischemic stroke as cases and 60 subjects as controls ( using simple nonr and om sampling ) . Homocysteine was measured by fluorimetric high-performance liquid chromatography .  Plasma folate and vitamin B12 levels were measured by an ion-capture method . Results : Mean plasma level of vitamin B12 in cases and controls were 358.4±290.3 Pg/ml and 369.8±110.4 Pg/ml , respectively which did not show any significant difference . Mean plasma level of folate in cases was significantly lower than the controls ( 6.8±4.5 ng/ml vs. 12.2±3.0 ng/ml , p=0.001 ) . It was also shown that mean plasma level of total homocysteine in cases was significantly higher than the controls ( 21.1±9.8 μM/L vs. 13.5±3.2 μM/L , P=0.001 ) . Homocysteine and folate but not plasma B12 had linear relation with age . Male cases had significantly lower Folate and B12 in contrast to women . In addition , male cases had significantly higher Homocysteine level in contrast to women . Conclusions : Our data shows that the level of homocysteine was higher and the level of folate was significantly lower in patients with ischemic stroke in contrast to controls . Effectiveness of supplementary folate and B 12 in such patients needs further well-structured prospect i ve placebo controlled studies
In this third up date of the Cochrane review , there were no differences in effects of homocysteine-lowering interventions in the form of supplements of vitamins B6 , B9 or B12 given alone or in combination comparing with placebo on myocardial infa rct ion , death from any cause or adverse events .
BACKGROUND Cardiovascular disease , which includes coronary artery disease , stroke and peripheral vascular disease , is a leading cause of death worldwide .
Homocysteine is an amino acid with biological functions in methionine metabolism .
A postulated risk factor for cardiovascular disease is an elevated circulating total homocysteine level .
The impact of homocysteine-lowering interventions , given to patients in the form of vitamins B6 , B9 or B12 supplements , on cardiovascular events has been investigated .
This is an up date of a review previously published in 2009 , 2013 , and 2015 .
OBJECTIVES To determine whether homocysteine-lowering interventions , provided to patients with and without pre-existing cardiovascular disease are effective in preventing cardiovascular events , as well as reducing all-cause mortality , and to evaluate their safety .